Ozempic®

Branded GLP-1. Weekly self-injection pen (Novo Nordisk)

FDA-approved GLP-1 receptor agonist for type 2 diabetes. Weight loss is a well-documented off-label effect.

Dosing: Set by your prescriber and adjusted over time based on how you respond.

Best for: Patients with type 2 diabetes who want a GLP-1 with proven glucose-lowering and appetite-regulation effects.

Key points

• FDA-approved for type 2 diabetes
• Same active ingredient as Wegovy® at diabetes-focused dosing
• HELiXVi clinician oversight throughout treatment

Considerations

• Weight-loss use may be off-label depending on indication
• Prescription-only, insurance coverage varies

Prescription treatment requires an online consultation with a licensed HELiXVi clinician. Individual results vary.

Start your free consultation right now

No clinic visit. Licensed US clinicians. Dispatched within 24 hours of your consultation and payment.

See the full weight loss program